415-050-0140 Admission The program must utilize an admission procedure that at a minimum must ensure the provision and documentation of the following: (1) Program orientation information must be offered in written format in a language understood by the patient. The orientation information must include: (a) A written description of the Program's services, including the Program's philosophical approach to stabilization; (b) Rights; (c) Responsibilities; (d) Grievance procedures; (e) Consent to services; and (f) Notice of Privacy Practices. (2) In accordance with ORS 179.505, 42 CFR Part 2, and HIPAA, an authorization for the release of information mustbe obtained for any confidential information concerning the patient being considered for, or receiving, services. (3) Screening for admission must meet the following requirements: (a) Patients must be considered for admission without regard to race, ethnicity, gender, gender identity, gender presentation, sexual orientation, religion, creed, national origin, age, except when program eligibility is restricted to children, adults or older adults, familial status, marital status, source of income, and disability; (b) When the patient is being treated for withdrawal from substance(s) other than the medication prescribed or dispensed to treat opioid dependence: (A) The provider may not deny admission to patients for the reason of a prescribed or dispensed medication to treat opioid dependence; and (B) The provider must support the continuation of access to the medication prescribed or dispensed to treat opioid dependence during the episode of care. (c) For patients receiving services funded by the SUPTR Block Grant, admission of pregnant patients to services must occur no later than 48 hours from the date of first contact, and no less than 14 days after the date of first contact for patients using substances intravenously. If services are not available within the required timeframe, the provider must document the reason and provide interim referral and informational services as defined in these rules, within 48 hours. (d) Admission of patients whose services are funded by the SUPTR Block Grant must be prioritized prior to admission in the following order through use of a screening that is documented in the service record: (A) Patients who are pregnant and using substances intravenously; (B) Patients who are pregnant; (C) Patients who are using substances intravenously; and (D) Patients with dependent children. (e) The admission screening service must be completed prior to rendering services and must document the rationale to recommend assessment for withdrawal management services. (4) Admission documentation must contain: (a) Substance use history; (b) Initial CIWA-Ar, COWS and/or other evidence-based measure of the severity of withdrawal symptoms; (c) Identification of the ASAM Level of Care placement through use of the ASAM Dimensional Admission Criteria; (d) Urinalysis collection and on-site testing of a urinary sample using a testing cup, stick or other on-site method; and (e) Decision by medical treatment staff to begin admission or to offer services on another date and/ or care coordination for other services. When services are not offered, the patient must be provided a list of community service organizations that may be of assistance. (5) The provider must report the admission and exit status, and any other data required by the Division in the mandated state data system for each patient whose services are paid for using public funding. Statutory/Other Authority: ORS 413.042 & 430.256 Statutes/Other Implemented: 430.345 - 430.375 & ORS 430.306 History: ADS 3-2023, amend filed 04/07/2023, effective 04/07/2023 ADS 1-2023, renumbered from 415-050-0025, filed 01/20/2023, effective 01/20/2023 ADS 6-2013, f. & cert. ef. 8-1-13 ADS 3-2013(Temp), f. & cert. ef. 2-4-13 thru 8-2-13 ADS 2-2008, f. & cert. ef. 11-13-08 ADAP 3-1993, f. & cert. ef. 12-6-93, Renumbered from 309-050-0025 MHD 15-1983, f. 7-27-83, cert. ef. 10-25-83, Renumbered from 309-052-0000(6) MHD 45, f. & cert. ef. 7-20-77 MHD 15(Temp), f. 1-16-74, cert. ef. 2-1-74